Your SlideShare is downloading. ×
0
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Nsclc 2nd line
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Nsclc 2nd line

654

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
654
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
40
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Second Line Treatment of metastatic Non-Small Cell Lung Cancer Update from the World Conference on Lung Cancer G. Nsouli MDTuesday, August 9, 2011
  • 2. Tuesday, August 9, 2011
  • 3. Tuesday, August 9, 2011
  • 4. Tuesday, August 9, 2011
  • 5. Weekly vs 3-weekly Docetaxel Overall survival (OAS) curves by treatment arm. Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With Once Every Week Second- Line Treatment of Advanced Non– Small-Cell Lung Cancer Di MaioTuesday, August 9, 2011 J.Clin. Oncol.
  • 6. Weekly vs 3-weekly Docetaxel Treatment effect on survival within major patient subgroups. PS, performance status. Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With Once Every Week Second- Line Treatment of Advanced Non– Small-Cell Lung Cancer Di MaioTuesday, August 9, 2011 J.Clin. Oncol.
  • 7. Pemetrexed vs. Docetaxel in second line Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non– Small-Cell Lung CancerPreviously Treated With ChemotherapyJ. Clin. Oncol 2004; 22:1589-97Tuesday, August 9, 2011
  • 8. Survival and Toxicity Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non– Small-Cell Lung CancerPreviously Treated With ChemotherapyJ. Clin. Oncol 2004; 22:1589-97Tuesday, August 9, 2011
  • 9. Median time to progression (A) for patients younger than 70 years of age: pemetrexed, 3.0 months v docetaxel, 3.9 months (hazard ratio [HR], 1.03; ; (B) for patients 70 years of age: pemetre-xed, 4.6 months v docetaxel, 2.9 months (HR,Benefit0.72; Elderly Patients From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized PhaseIII Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non– Small-Cell Lung Cancer Weiss G J.Clin. Oncol. 006;24:4405-11Tuesday, August 9, 2011
  • 10. Median overall survival time (A) for patients younger than 70 years of age: pemetrexed, 7.8 months v docetaxel, 8.0 months HR], 1.02; (B) for patients 70 years of age: pemetrexed, 9.5 months v docetaxel, 7.7 months (HR, 0.86; Patients Benefit Elderly From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized PhaseIII Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non– Small-Cell Lung Cancer Weiss G J.Clin. Oncol. 006;24:4405-11Tuesday, August 9, 2011
  • 11. Current Guidelines in Second line treatment of NSCLC • For patients with disseminated metastatic disease, both second-line cytotoxic chemotherapy and small molecule epidermal growth factor receptor (EGFR) inhibitors may provide palliation and increase survival. • When symptoms are due to progressive disease within the chest or from metastatic involvement of a single or limited number of sites, radiation therapy (RT) is often useful for palliation.Tuesday, August 9, 2011
  • 12. Tuesday, August 9, 2011
  • 13. Tuesday, August 9, 2011
  • 14. Tuesday, August 9, 2011
  • 15. Tuesday, August 9, 2011
  • 16. Tuesday, August 9, 2011
  • 17. Tuesday, August 9, 2011
  • 18. Tuesday, August 9, 2011
  • 19. Tuesday, August 9, 2011
  • 20. Tuesday, August 9, 2011
  • 21. Tuesday, August 9, 2011
  • 22. Tuesday, August 9, 2011
  • 23. Tuesday, August 9, 2011
  • 24. Tuesday, August 9, 2011
  • 25. Tuesday, August 9, 2011
  • 26. Tuesday, August 9, 2011
  • 27. Tuesday, August 9, 2011
  • 28. Tuesday, August 9, 2011
  • 29. Tuesday, August 9, 2011
  • 30. Tuesday, August 9, 2011
  • 31. Tuesday, August 9, 2011
  • 32. Tuesday, August 9, 2011
  • 33. Tuesday, August 9, 2011
  • 34. Tuesday, August 9, 2011
  • 35. Tuesday, August 9, 2011
  • 36. Tuesday, August 9, 2011
  • 37. Tuesday, August 9, 2011
  • 38. Tuesday, August 9, 2011
  • 39. Tuesday, August 9, 2011
  • 40. Tuesday, August 9, 2011
  • 41. Tuesday, August 9, 2011
  • 42. Tuesday, August 9, 2011
  • 43. Tuesday, August 9, 2011

×